Bluebird bio Inc

Bluebird bio — ASH 2019

38 slides from Bluebird bio's conference presentation, Dec 10, 2019

  1. Slide 1: ASH 2019

    ASH 2019 december 9, 2019 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions a

  3. Slide 3: Today's agenda

    today’s agenda welcome Nick Leschly chief bluebird LentiGlobin for TDT data Dave Davidson, M.D. chief medical officer LentiGlobin for SCD data Mohammed Asmal, M.D., Ph.D. vice president, head of SGD clinical research bb21217 and KarMMa topline data Dave Davidson, M.D. chief medical officer Q&A Chip

  4. Slide 4: Radical care: we recode for life

    RADICAL CARE We care in a way that’s intense and truly sets us apart. WE RECODE FOR LIFE THIS IS PERSONAL Gene therapy is about saving lives one person at a time. And we are, each of us, personally all in. PIONEERS WITH PURPOSE We’re exploring new frontiers for the sake of patients.

  5. Slide 5: We live by our non-negotiables

    We live by our non-negotiables

  6. Slide 6: Key questions for today

    Key questions for today LentiGlobin TDT LentiGlobin SCD bb21217 Do the updated data in patients with non-β0/β0 genotypes reinforce the potential for patients to achieve and maintain transfusion independence (TI)? Do the emerging data in patients with β0/β0 genotypes suggest that these patients may a

  7. Slide 7: Transfusion-Dependent β-Thalassemia (TDT) program overview

    Transfusion-Dependent β-Thalassemia (TDT) EU approval granted June 2019 US rolling BLA submission to begin by YE 2019 Studies ongoing: Northstar-2 (HGB-207) Northstar-3 (HGB-212) Long-term follow-up: LTF-303 program overview A severe, progressive, genetic disease that leads to severe anemia, lifelon

  8. Slide 8: Completed studies of LentiGlobin for TDT reinforce long term durability

    Completed studies of LentiGlobin for TDT reinforce long term durability of clinical outcomes Up to 5 years follow-up with stable HbAT87Q and total Hb 8/10 non-β0/β0; 3/8 β0/β0 remain TI as of data cut-off Reduction in liver iron content; cardiac iron remains stable in normal range as of data cut-off

  9. Slide 9: HGB-207: 90% of patients off pRBC transfusions

    HGB-207: 90% (18/20) of patients with > 3 months follow-up are off pRBC transfusions Data as of 12 June 2019 Green indicates patient <12 years old at screening Hb (g/dL) at last visit The safety profile of LentiGlobin for TDT remains generally consistent with that of myeloablative busulfan condition

  10. Slide 10: HGB-207: stable total Hb and HbAT87Q

    HGB-207: stable total Hb and gene therapy-derived HbAT87Q in the majority of patients Data as of 12 June 2019 *Last Hb before patient 2 restarted red blood cell transfusions. Hb, hemoglobin. Median total Hb values include Patient 2 who was on transfusions Median Hb (g/dL) M6 N=17 M9 N=14 M12 N=11 M1

  11. Slide 11: HGB-212: 9/11 patients off transfusions for ≥3 months

    HGB-212: 9/11 patients with ≥ 6 months follow-up have been off transfusions for ≥ 3 months Data as of 30 September 2019 Hb, hemoglobin; RBC, red blood cell 13.2 10.4 14.2 7.8* 9.4 12.8 9.7 9.6* 10.0 11.1 8.3 9.8* 1 2 3 4 5 6 7 8 9 10 11 12 Genotype β0/β0 β0/IVS I-110 IVS I-110/IVS I-110 β0/β0 β0/IVS

  12. Slide 12: HGB-212: HbAT87Q supports target total Hb

    HGB-212: HbAT87Q supports target total Hb in most patients with minimal endogenous HbA ≥ 3 months after treatment Data as of 30 September 2019 DP, drug product; Hb, hemoglobin; VCN, vector copy number Genotype β0/β0 β0/ IVS I-110 IVS I-110/ IVS I-110 IVS I-110/ IVS I-110 β0/β0 β0/ IVS I-110 β0/β0 β0

  13. Slide 13: 50+ patients treated across program for LentiGlobin in TDT

    50+ patients treated across program for LentiGlobin in TDT Completed HGB-204 and HGB-205 studies with up to 5+ years of data reinforce durability of treatment 90% of evaluable patients who do not have a β 0 / β 0 genotype achieved TI in HGB-207 study 9 of 11 patients with at least 6 months of follow

  14. Slide 14: Sickle Cell Disease (SCD) program overview

    Sickle Cell Disease (SCD) Plan to pursue development path based on hematological primary endpoint Phase 3 HGB-210 study to be open and enrolling patients by early 2020 HGB-206 target enrollment achieved program overview A serious, progressive, unpredictable, and debilitating genetic disease caused b

  15. Slide 15: HGB-206 study design and patient disposition

    Ongoing Phase 1/2, single arm, multi-center, U.S. study N=41 (Group C) Primary Endpoint: HbAT87Q and total Hb Key Secondary Endpoint: Reduction in severe VOEs ≥ 12 years of age - ≤ 50 years of age Phase 1/2, single-center in France N=7 (4 β-thalassemia) HGB-205 (Transfusion-dependent b-thalassemia &

  16. Slide 16: 99% reduction in annualized rate of VOC + ACS

    99% reduction in annualized rate of VOC + ACS in HGB-206 Group C patients with history of VOCs and ACS who had ≥ 6 months of follow-up *As previously reported, 1 non-serious Grade 2 VOC was observed in 1 patient ~3.5 months post-LentiGlobin treatment Investigator-reported adverse events of VOC or AC

  17. Slide 17: Improving key markers of hemolysis in HGB-206 Group C

    Improving key markers of hemolysis in HGB-206 Group C patients following treatment with LentiGlobin for SCD Median (Q1, Q3) depicted; Dot-dash lines denote lower and upper limits of normal values; *Number of patients with data available; †Total bilirubin at last follow-up remains > 2-fold lower than

  18. Slide 18: Consistent median levels of anti-sickling hemoglobin

    HGB-206 Group C patients at 6 months post-treatment produced consistent median levels of anti-sickling hemoglobin ranging from 44% - 59% (Month 6-21) Median Hb (g/dL) % represents median Hb fraction as % of total Hb; Hb, hemoglobin 38% 44% 34% 53% 54% 48% 50% 44% 52% 44% 53% 45% 59% 39% Median HbS ≤

  19. Slide 19: ≥70% of RBCs contain βA-T87Q by month 6

    On average, ≥ 70% of RBCs from patients treated with LentiGlobin for SCD contain βA-T87Q by month 6 Exploratory single RBC western assay performed on samples from 12 patients in Group C DP, drug product; RBCs, red blood cells; sc, single cell Mean is depicted - if N=1, data show technical replicates

  20. Slide 20: Exploratory assay: high concentrations of T87Q at cellular level

    Exploratory assay: high concentrations of T87Q achieved at the cellular level DP, drug product; Hb, hemoglobin; HPFH, hereditary persistence of fetal hemoglobin; MCH, mean corpuscular hemoglobin; RBC, red blood cells AS, sickle cell trait; HD, healthy donor; SS, sickle mutation on both HBB alleles A

  21. Slide 21: HGB-206 Group C: safety profile post-DP infusion

    HGB-206 Group C: safety profile post-DP infusion generally consistent with myeloablative single-agent busulfan conditioning Non-hematologic Grade ≥ 3 AEs Post-DP infusion in ≥ 2 patients* N = 17 n (%) Febrile neutropenia 10 (58.8) Stomatitis 9 (52.9) Increased blood bilirubin 3 (17.6) Upper abdomina

  22. Slide 22: Notable impact on underlying pathophysiology of SCD

    Notable impact on underlying pathophysiology of SCD ACS, acute chest syndrome; VOCs, vaso-occlusive crises 99% reduction in annualized rate of VOC + ACS in Group C patients with history of VOCs and ACS who had ≥ 6 months of follow-up, with no reports of ACS or serious VOCs at up to 21 months post-tr

  23. Slide 23: Multiple myeloma BCMA program overview

    multiple myeloma ide-cel (bb2121): U.S. BLA submission planned for 1H:2020 KarMMa-2 and KarMMa-3 studies in earlier lines of therapy open and enrolling; Phase 1 study in newly-diagnosed multiple myeloma set for 2019 bb21217 CRB-402 Phase 1 study underway BCMA program overview An incurable type of bl

  24. Slide 24: Hypothesis: memory-like T cell subsets and bb21217

    Hypothesis: Increasing long-lived, memory-like T Cell subsets in the drug product may result in enhanced persistence of functional anti-BCMA CAR T cells in vivo TN cell TSCM cell TCM cell TEM cell TEFF cell Terminally Differentiated No Self Renewal Short-lived bb21217: PI3K inhibition during manufac

  25. Slide 25: Phase 1 dose-escalation study continues to enroll

    300 × 106 n=6 Phase 1 dose-escalation study in heavily pretreated and refractory patient population continues to enroll BCMA, B-cell maturation antigen; IMiD, immunomodulatory imide drugs; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival; PI, proteasome inhibitor;

  26. Slide 26: Baseline patient characteristics and treatment history

    Baseline patient characteristics and treatment history Confidential : DRAFT Data as of 4 September 2019 Characteristic bb21217-Treated (N=38) Median (min, max) age, y 62 (33, 74) Male, n (%) 21 (55) Time since initial diagnosis, y Median (min, max) 5.5 (1.0, 13.5) ECOG PS, n (%) 0 1 2 12 (32) 24 (63

  27. Slide 27: Safety profile consistent with CAR T experience

    Safety profile consistent with CAR T experience Confidential : DRAFT Data as of 4 September 2019 CRSc occurred in 25 patients (66%) Median (min, max) time to onset was 3 d (1, 20) Generally adequately managed with tocilizumab (n=10) and tocilizumab plus corticosteroids (n=4) 1 fatal CRS event associ

  28. Slide 28: Responses by dose cohort

    Data as of 4 September 2019 CAR+ T Cells N Median follow up (min, max) 150 × 106 12 17.6 mo (12, 23) 300 × 106 14 4.0 mo (2, 10) 450 × 106 12a 3.3 mo (<1, 6) Months CR, complete response; MRD, minimal residual disease; PD, progressive disease; sCR, stringent complete response; VGPR, very good partia

  29. Slide 29: Confirmed response duration by dose

    Data as of 4 September 2019 Confirmed Response Duration by Dosea DOR, duration of response; MRD, minimal residual disease; NE, not estimable; PD, progressive disease; PR, partial response; sCR/CR, stringent complete response/complete response; VGPR, very good partial response. aPatients with ≥2 mont

  30. Slide 30: Confirmed responders show increased CAR T expansion and persistence

    Confirmed responders show increased CAR T cell expansion and durable persistence Confidential : DRAFT Data as of 4 September 2019 Month 3 6 12 18 Detectable vectora, n 13 8 2 2 No. at riskb 15 10 4 2 Median VCN Over Time by Dose Vector Copies/μg gDNA Months After bb21217 Infusion P value based on a

  31. Slide 31: Enrichment for memory-like T cells and CAR T expansion

    Proportion LEF1+ t cells Proprortion CD57+ t cells Enrichment for memory-like T cells is associated with robust CAR T expansion and lack of progression by month 6 Patients with a higher proportion of memory-like T cells in bb21217 drug product have significantly better peak expansion A higher propor

  32. Slide 32: Emerging data supports memory T cell hypothesis

    Emerging data supports memory T cell hypothesis Confidential : DRAFT Safety profile consistent with known toxicities of CAR T-cell therapies Demonstrated association between enrichment in 21217 manufacturing process and robust CAR-T cell expansion Dose escalation is complete. Continue to evaluate sa

  33. Slide 33: KarMMa topline data readout

    KarMMa topline data readout

  34. Slide 34: KarMMa topline results in heavily pretreated population

    Heavily pretreated population 94% refractory to anti-CD38, 84% triple refractory All patients were refractory to their last treatment (progression during or within 60 days of last therapy) Deep and durable responses across dose levels mPFS of >11mo at the 450 x 106 dose Durability is consistent acro

  35. Slide 35: Advancing ide-cel into earlier lines of multiple myeloma

    Advancing ide-cel (bb2121) into earlier lines of multiple myeloma Multiple Myeloma NDMM Study KarMMa-3 (BB2121-MM-003) KarMMa-2 (BB2121-MM-002) KarMMa (BB2121-MM-001) phase 3 phase 2 phase 1 registration-enabling trial in late line met primary and secondary endpoints front line setting Phase 1 study

  36. Slide 36: Closing

    closing

  37. Slide 37: bluebird bio at ASH 2019

    bbb at ASH 2019: LentiGlobin TDT LentiGlobin SCD bb21217 Patients achieving and maintaining TI across genotypes Launch progressing in EU Clinical impact underscored by impact on underlying disease Program gradually expanding Indication of hypothesis bearing out Further investigation underway bb2121

  38. Slide 38: Thank you

    thank you

bluebird bio — ASH 2019 on 6ix